Core Viewpoint - The company held a Q3 2025 earnings presentation on November 19, 2025, to discuss its financial status, market expansion, R&D projects, and future strategies with investors [1][2]. Group 1: Earnings Presentation Overview - The earnings presentation was conducted via the Shanghai Stock Exchange's online platform, with key executives including the chairman and CFO in attendance [2]. - The company disclosed its Q3 2025 report on October 29, 2025, prior to the earnings presentation [1]. Group 2: Investor Questions and Company Responses - The company is focusing on expanding its sales channels to include outpatient markets and grassroots medical institutions, aiming to integrate resources across different healthcare settings [3]. - The market demand for steroid hormones and amino acids is competitive, prompting the company to concentrate on core areas such as dermatology and respiratory health while enhancing its product pipeline [3]. - The company anticipates challenges in achieving its 2025 annual performance targets due to price reductions from centralized procurement and intensified competition, but it plans to adapt its sales strategies and enhance market operations [3]. - Recent product developments include two products passing the consistency evaluation for generic drug quality and efficacy, and several products receiving registration certificates [4]. - The company reported that the market prospects for butorphanol tartrate injection are promising, with projected sales of CNY 1.965 billion in 2023 and CNY 1.899 billion in 2024 [4]. - The company emphasizes its commitment to returning value to investors, maintaining a cash dividend ratio exceeding 80% since 2023, and focusing on sustainable growth [4]. - The company is enhancing its compliance management systems and conducting regular training to foster a strong compliance culture [4].

Core Viewpoint - The legal opinion letter from Changshi Law Firm confirms that the 2025 Second Extraordinary General Meeting of Tianjin Pharmaceutical Co., Ltd. was convened and conducted in accordance with relevant laws, regulations, and the company's articles of association [1][8]. Group 1: Meeting Procedures - The meeting was convened based on a resolution from the 17th meeting of the 9th Board of Directors held on June 25, 2025, and the notice was published on June 26, 2025 [3][4]. - The meeting was held on July 15, 2025, at the specified location, and the actual time and place matched the notice [4][6]. - A network voting platform was provided for shareholders, allowing them to vote during specified times [4][7]. Group 2: Attendance and Qualifications - A total of 8 shareholders and their proxies attended the meeting, representing 9,243,482 shares, which is 0.8466% of the total voting shares [4][5]. - Additionally, 293 shareholders participated via the network voting system, representing 36,877,352 shares, or 3.3377% of the total voting shares [5]. - The qualifications of all attendees, including the convenor, were verified to be in compliance with relevant laws and the company's articles of association [5][6]. Group 3: Voting Results - The first agenda item regarding the mortgage application for a loan by a controlling subsidiary was approved with 43,376,634 votes in favor (94.0499%), 1,999,800 votes against (4.3360%), and 744,400 abstentions (1.6141%) [6][8]. - The voting procedures and results were confirmed to be valid and in accordance with legal requirements and the company's articles of association [8].

津药药业股份有限公司 津药药业股份有限公司 会议资料 津药药业股份有限公司 $$\langle\exists\exists\exists\exists\exists\forall\exists\exists\exists\exists\exists\exists$$ 津药药业 2025 年第二次临时股东大会会议议案之一 关于控股子公司以自有资产抵押申请贷款 暨关联交易的议案 (已经 2025 年 6 月 25 日第九届董事会第 17 次会议审议通过) 一、关联交易概述 （一）本次交易的基本情况 津药药业股份有限公司(以下简称"公司")于 2023 年 12 月 20 日经第九届董事会第三次会议、2024 年 1 月 10 日经 2024 年第一次 临时股东大会审议通过"关于公司与天津医药集团财务有限公司关联 交易的议案"，公司与天津医药集团财务有限公司（以下简称"财务 公司" ）签订《金融服务协议》，财务公司向公司提供金融服务总额不 超过 12.03 亿元（详见公司公告 2023-086#）。 公司于 2024 年 6 月 17 日经第九届董事会第八次会议与公司第九 届监事会第六次会议审议通过"关于控股子公司 ...

Regulatory Developments - The National Medical Products Administration (NMPA) is seeking opinions on optimizing the review and approval process for innovative drug clinical trials, proposing a 30-day fast track for applications of traditional Chinese medicine, chemical drugs, and biological products classified as Category 1 innovative drugs [1] - The application must meet specific criteria, including being a key innovative drug supported by national policies, included in special programs for children's drugs or rare diseases, or part of global synchronized research [1] Company Announcements - Shanghai Aikobio announced that its new drug application for Aizhida (a combination capsule for ADHD) has been accepted by the NMPA and is included in the priority review process [1] - WuXi Biologics announced a placement of 82.94 million existing shares at HKD 26.60 per share, representing approximately 2.04% of its total issued share capital [2] - Jichuan Pharmaceutical disclosed that after a share transfer, Cao Fei and Cao Longxiang became the joint actual controllers of the company, holding a combined 56.07% of the total share capital [3] - Wuhan Dazhong Oral Medical Co., Ltd. has received IPO approval to list on the Hong Kong Stock Exchange, operating 92 dental clinics across Hubei and Hunan provinces [4][5] Market Dynamics - Three Leaf Clover Biotech announced the termination of its exclusive agreement with Guoguang Biotechnology due to significant market changes, ceasing the distribution of a seasonal flu vaccine in mainland China [6] - Sanofi has re-entered the flu vaccine market after receiving approval for its quadrivalent flu vaccine for the 2025-2026 season, following a previous suspension due to efficacy issues [6] - Zhejiang Province's government procurement center announced the results for flu vaccine procurement, with prices as low as 6 CNY per dose, marking a new low for flu vaccine bids [6] Safety Concerns - Sarepta Therapeutics reported a second death related to its DMD gene therapy Elevidys, leading to a suspension of the drug's supply for non-ambulatory patients [7] Regulatory Actions - The State Administration for Market Regulation imposed a total fine of 362 million CNY on several pharmaceutical companies for engaging in price-fixing agreements [8]

Meeting Information - The annual general meeting of Tianjin Pharmaceutical Industry Co., Ltd. is scheduled for April 16, 2025, at 14:00 [1] - The meeting will take place at the company's office located at 221 Huanghai Road, Tianjin Economic and Technological Development Zone [1] - Shareholders can participate through both on-site and online voting methods [2] Voting Procedures - The online voting system will be provided by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [1][2] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [3][4] - The company will utilize a reminder service to notify shareholders about the meeting and voting procedures [3] Attendance and Registration - Only shareholders registered by the close of trading on April 9, 2025, are eligible to attend the meeting [5] - Registration for attendance must be completed by April 15, 2025, with specific documentation required [5][6] - The meeting will last for half a day, and attendees are responsible for their own travel and accommodation expenses [6]

现金分红比例（%） 223.65 现金分红比例（E）是否低于30% 否 是否触及《股票上市规则》第9.8.1条第一 款第（八）项规定的可能被实施其他风险 否 警示的情形 二、公司履行的决策程序 重要内容提示： ? 每 10 股派发现金红利 0.98 元（含税）。 ? 本次利润分配以实施权益分派股权登记日登记的总股份数为基数， 具体日期将在权益分派实施公告中明确。 ? 在实施权益分派的股权登记日前公司总股份数发生变动的，拟维持 每股分配比例不变，相应调整分配总额，并将另行公告具体调整情 况。 ? 不触及《上海证券交易所股票上市规则（2024 年 4 月修订）》第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、2024 年度利润分配预案内容 （一）利润分配预案的具体内容 （一）董事会会议的召开、审议和表决情况 津药药业: 津药药业股份有限公司2024年度利润分 配预案的公告 证券代码：600488 证券简称：津药药业 编号：2025-017 津药药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及 ...

Group 1 - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration [1] - The drug is an opioid receptor antagonist, and the company has invested approximately 4.2 million yuan in the research and development of this product [1][2] - The domestic sales of Naloxone Hydrochloride Injection were 413 million yuan in 2022 and are projected to be 535 million yuan in 2023, indicating a growth in market demand [2] Group 2 - The approval of the drug registration certificate enhances the company's formulation product portfolio and is expected to positively impact the company's performance in the domestic formulation market [3] - However, the sales timeline, scale, and future expansion of the drug in the domestic market remain uncertain due to competitive market conditions [3]